{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:15:49Z","timestamp":1774991749807,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic spontaneous urticaria (CSU) is a highly prevalent and difficult to manage cutaneous disease characterized by the presence of recurrent urticaria, angioedema, or both, for a period of 6 weeks or longer. One of the biological treatments used for patients with CSU with an autoimmune background and bad control of the disease is omalizumab, an anti-IgE monoclonal antibody. The understanding of the mechanism of action of this biological drug in CSU along with the identification of potential biomarkers of clinical response can be helpful in the personalized management of the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this study was to analyze the effect of omalizumab on peripheral blood lymphocyte subpopulations in patients with CSU in order to identify potential biomarkers of treatment response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed 71 patients with CSU [33 under omalizumab and 38 under non-immunomodulatory drugs (treated with antihistamines; NID)] and 50 healthy controls. An exhaustive immunophenotyping of whole blood T-cell subpopulations, including na\u00efve, central memory, effector memory, effector cells, Th1, Th2, and Th17 was performed by multiparametric flow cytometry. Moreover, in CSU patients, we analyzed markers of inflammation (ESR, DD, CRP), atopy (prick test, IgE quantification), and autoimmunity (anti-thyroid antibodies and indirect basophil activation test).To evaluate the clinical activity, the Urticaria Activity Score 7 (UAS 7) test was used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In patients with CSU under treatment with omalizumab, there was a significant decrease in the percentage of na\u00efve and an increase in the percentage of central memory CD4 T cells as well as a decrease in the percentage of na\u00efve and increase in the percentage of effector CD8 T-cell subsets. Moreover, patients under treatment with omalizumab had higher percentages of Th1 and Th2 cells than patients under treatment with NID.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The immune monitoring of T-cell subpopulations in patients with CSU starting omalizumab, may be a useful strategy to analyze treatment response in the clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1413233","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:47:35Z","timestamp":1724129255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients"],"prefix":"10.3389","volume":"15","author":[{"given":"Cristina","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Depreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Bielsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Roger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibiana","family":"Quirant-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Basaga\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanina","family":"Jurgens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Padr\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sira","family":"Miquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Martinez-Caceres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Teniente-Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0151-9638(14)70158-9","article-title":"Pathophysiology of urticaria","volume":"141","author":"Nosbaum","year":"2014","journal-title":"Ann Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/CRIAI:30:1","article-title":"Pathophysiology of urticaria","volume":"30","author":"Hennino","year":"2006","journal-title":"Clin Rev Allergy Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: Associations found in a large population study","volume":"129","author":"Confino-Cohen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00627","article-title":"Autoimmune theories of chronic spontaneous urticaria","volume":"10","author":"Bracken","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12465","article-title":"Management of urticaria: Not too complicated, not too simple","volume":"45","author":"Ferrer","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.003","article-title":"Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review","volume":"16","author":"Kolkhir","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00805.x","article-title":"Role of the subgroups of T, B, natural killer lymphocyte and serum levels of interleukin-15, interleukin-21 and immunoglobulin e in the pathogenesis of urticaria","volume":"37","author":"Huilan","year":"2010","journal-title":"J Dermatol"},{"key":"B9","article-title":"The profiles of T lymphocytes and subsets in peripheral blood of patients with chronic idiopathic urticaria","volume":"9","author":"Chen","year":"2016","journal-title":"Int J Clin Exp Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000073719","article-title":"Correlation between T-cell and mast cell activity in patients with chronic urticaria","volume":"132","author":"Hidv\u00e9gi","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaci.2016.04.036","article-title":"Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor I\u03b1 subunit","volume":"138","author":"Auyeung","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(83)90629-2","article-title":"Lymphocyte subpopulations in the skin of patients with chronic urticaria","volume":"72","author":"Mekori","year":"1983","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cea.12870","article-title":"Potential blood biomarkers in chronic spontaneous urticaria","volume":"47","author":"Kolkhir","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/JAA","article-title":"Biomarkers in chronic spontaneous urticaria: Current targets and clinical implications","volume":"12","author":"Puxeddu","year":"2019","journal-title":"J Asthma Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil Fc3 RI expression in chronic spontaneous urticaria: A potential immunological predictor of response to omalizumab therapy","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/1872213X13666190328164931","article-title":"Chronic urticaria: an overview of treatment and recent patents","volume":"13","author":"Hon","year":"2019","journal-title":"Recent Pat Inflammation Allergy Drug Discovery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.07.005","article-title":"Algorithm for treatment of chronic spontaneous urticaria with omalizumab","volume":"109","author":"Spertino","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.01.013","article-title":"Predictive immunomonitoring-The COST ENTIRE initiative","volume":"147","author":"Popadic","year":"2013","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the human immunology project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13491","article-title":"Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe","volume":"202","author":"Oras","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.742470","article-title":"What basophil testing tells us about CSU patients \u2013 results of the CORSA study","volume":"12","author":"Marcelino","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.125","article-title":"Basophil activation test identifies the patients with chronic spontaneous urticaria suffering the most active disease","volume":"4","author":"Curto-Barredo","year":"2016","journal-title":"Immunity Inflammation Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/all.14747","article-title":"Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice","volume":"76","author":"Santos","year":"2021","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/all.2017.72.issue-4","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-011-1144-x","article-title":"Autologous serum skin test response in chronic spontaneous urticaria and respiratory diseases and its relationship with serum interleukin-18 level","volume":"303","author":"Kurt","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2011.09.009","article-title":"Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test","volume":"40","author":"Rodr\u00edguez-Trabado","year":"2012","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.033","article-title":"The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells","volume":"9","author":"Gim\u00e9nez-Arnau","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02191.x","article-title":"Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy","volume":"35","author":"Holgate","year":"2005","journal-title":"Clin Exp Allergy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1413233\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:47:39Z","timestamp":1724129259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1413233\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2024.1413233"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1413233","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"article-number":"1413233"}}